(i) Commencing the date of this Agreement, subject to any applicable Regulations, each Holder, as applicable, together with its affiliates, shall be entitled to convert the Note or Preferred Stock or exercise the Warrant and sell the underlying shares, in accordance with the restrictions contained on Schedule A (the “Leak Out”). The Leak Out will remain in effect until the earlier of the date the Company holds a stockholder vote on whether to increase the Company’s authorized common stock to 500,000,000 shares (including any adjourned meeting dates), or April 30, 2016, unless otherwise expressly extended in writing by the Holders (the “Leak Out Period”), at which time the Holders shall no longer be subject to the Leak Out restrictions, and shall be entitled to convert and exercise the Securities, as the Holders in their sole discretion may determine.
(ii) Upon a breach of any representation, warranty or covenant of the Company pursuant to this Agreement, the Company shall be entitled to a two (2) day cure period (the “Cure Period”). During the Cure Period the Holders shall no longer be subject to the Leak Out restrictions until such time as the Company provides written notification and demonstrable proof that such breach has been cured. If such breach is not cured to the satisfaction of any of the Holders during the Cure Period, any of the Holders may submit written notification of such breach to the Company and the Holders shall no longer be subject to the Leak Out restrictions, subject to any applicable Regulations.
(iii) The Company shall facilitate any conversion notice or exercise notice received from the Holders, and shall cause to be issued such shares, as contained in such conversion notice or exercise notice, on a timely basis, as provided for in the respective Security.
1
